Status:
COMPLETED
Adenosine Dual Source Computed Tomography (CT) Versus Adenosine Single Photon Emission Computed Tomography (SPECT)
Lead Sponsor:
Cedars-Sinai Medical Center
Collaborating Sponsors:
Astellas Pharma US, Inc.
Conditions:
Coronary Artery Disease
Eligibility:
All Genders
18+ years
Brief Summary
Researchers hope that this new non-invasive multi-detector scanner (DSCT) will provide diagnostic information comparable to the combination of traditional SPECT (for function and blood flow) and CT im...
Detailed Description
The DSCT scanner is able to assess cardiac blood flow (myocardial perfusion) at the same time as coronary anatomy. The results derived from these scans will be compared to standard SPECT imaging. To ...
Eligibility Criteria
Inclusion
- Pilot 1:
- Provide written consent and are willing to comply with protocol requirements
- Are at least 18 years of age
- Are referred for clinically-ordered SPECT
- Have known CAD
Exclusion
- Patients being referred to invasive coronary angiography will not be included in this pilot
- Caffeine intake within the 24 hours prior to adenosine stress testing
- Pregnancy (known or suspected)
- Intolerance or contraindication to adenosine (severe Asthma…)
- Intake of methylxanthine containing medications such as theophylline that have not been withdrawn and would interfere with the effectiveness of adenosine.
- Unstable coronary syndromes
- Uncontrolled congestive cardiac failure or cardiogenic shock
- Uncontrolled hypertension with resting BP \> 200/110
- More than 30 days between the Adeno-SPECT and the Adeno-DSCT
- Revascularization (percutaneous coronary intervention or coronary artery bypass graft surgery) between the Adeno-SPECT and the Adeno-DSCT
- Change in clinical status as determined by the investigator
- Inability to be on same medication regime 24 hrs prior to Adeno-SPECT and Adeno DSCT
- Patients with chronic renal failure (C.C.T. \< 60 ml/m2/sec)
- Patients with allergy to contrast iodinated media
- Congestive heart failure
- History of thromboembolic disorders
- Multiple myeloma
- Hyperthyroidism
- Pheochromocytoma
- Atrial fibrillation
- Inability to perform breath hold for 12 seconds
- Pilot 2:
- All inclusions/exclusions are the same as Pilot 1, WITH THE ADDITION OF:
- Inclusion Criteria:
- Have had prior (within 30 days) positive Adeno-SPECT scan
Key Trial Info
Start Date :
February 1 2007
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 1 2011
Estimated Enrollment :
34 Patients enrolled
Trial Details
Trial ID
NCT00892307
Start Date
February 1 2007
End Date
May 1 2011
Last Update
November 13 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cedars-Sinai Medical Center
Los Angeles, California, United States, 90048